DBV Technologies (NASDAQ:DBVT) Earns Hold Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of DBV Technologies (NASDAQ:DBVT) in a report issued on Friday. The firm issued a hold rating on the stock.

Several other research analysts have also recently commented on DBVT. JMP Securities reaffirmed a “market outperform” rating and set a $5.00 target price on shares of DBV Technologies in a report on Tuesday, September 24th. HC Wainwright lifted their price objective on DBV Technologies from $5.00 to $7.00 and gave the company a “buy” rating in a report on Thursday, October 24th.

DBV Technologies Trading Down 3.9 %

DBV Technologies stock opened at $0.47 on Friday. The company has a market capitalization of $45.26 million, a price-to-earnings ratio of -0.52 and a beta of 0.66. DBV Technologies has a 12 month low of $0.44 and a 12 month high of $2.14. The stock’s 50 day moving average is $0.70 and its 200-day moving average is $0.85.

DBV Technologies shares are set to reverse split on the morning of Friday, November 29th. The 1-5 reverse split was announced on Monday, November 11th. The number of shares owned by shareholders will be adjusted after the closing bell on Thursday, November 28th.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in DBV Technologies stock. Yiheng Capital Management L.P. grew its position in DBV Technologies S.A. (NASDAQ:DBVT) by 6.2% in the first quarter, according to its most recent filing with the SEC. The fund owned 5,568,909 shares of the company’s stock after acquiring an additional 327,345 shares during the period. DBV Technologies accounts for approximately 0.2% of Yiheng Capital Management L.P.’s investment portfolio, making the stock its 15th biggest position. Yiheng Capital Management L.P. owned 2.89% of DBV Technologies worth $4,172,000 at the end of the most recent reporting period. 71.74% of the stock is currently owned by institutional investors and hedge funds.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.